Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425386 · ClinicalTrials.gov registry record · Phase 2
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
A Phase 2 study of Kidney Cancer, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT00425386: Completed Phase 2 study of Kidney Cancer, sponsored by OHSU Knight Cancer Institute.
NCT00425386 is a Phase 2 study of Kidney Cancer that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 60 participants, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00425386, a Phase 2 study of Kidney Cancer, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying the best dose of erlotinib when given together with sunitinib and to see how well they work in treating patients with unresectable or metastatic kidney cancer.
Primary Outcome
The MTD is defined as the dose that produces dose limiting toxicity (DLT) in 33% of the patients.
Conditions Studied
Interventions
- PROCEDURE biopsy
- DRUG erlotinib hydrochloride
- DRUG sunitinib malate
Study Locations (4)
Oregon
- Providence Cancer Center at Providence Portland Medical Center - Portland
- OHSU Knight Cancer Institute - Portland
- Salem Hospital - Salem
California
- University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
What the finished NCT00425386 record still lists
NCT00425386 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 3 interventions - of which biopsy is the first listed.
NCT00425386 reports a single indexed study location in Oregon, California.
Frequently Asked Questions
What is clinical trial NCT00425386 about?
NCT00425386 is a clinical study titled "Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer". RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying the best dose of erlotini...
What is the current status of trial NCT00425386?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-08. Estimated completion is 2014-03.
What conditions does trial NCT00425386 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00425386?
The interventions under investigation include: biopsy (PROCEDURE), erlotinib hydrochloride (DRUG), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00425386?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00425386 being conducted?
This trial has 4 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00425386's enrollment target sits among peer trials
60 30th of 60 higher than 29 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia